MARKET

LGND

LGND

Ligand Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

144.40
+2.69
+1.90%
After Hours: 143.96 -0.44 -0.30% 16:20 03/05 EST
OPEN
141.36
PREV CLOSE
141.71
HIGH
147.16
LOW
135.34
VOLUME
360.24K
TURNOVER
--
52 WEEK HIGH
219.75
52 WEEK LOW
57.24
MARKET CAP
2.40B
P/E (TTM)
-739.7541
1D
5D
1M
3M
1Y
5Y
Why Is Ligand (LGND) Down 21.3% Since Last Earnings Report?
Zacks.com · 2d ago
These are the most shorted stocks in the U.S. right now
Heavily-shorted stocks have been making the headlines in recent weeks after a deluge of retail investment led the share price of GameStop and others to skyrocket.
CNBC.com · 02/25 20:09
Here Are The Stocks With The Highest Short Interest Rate
Short interest rates can be used to predict the potential direction of an individual stock.
Benzinga · 02/25 14:55
These are the most shorted stocks in the U.S. right now
Heavily-shorted stocks have been making the headlines in recent weeks after a deluge of retail investment led the share price of GameStop and others to skyrocket.
CNBC.com · 02/22 15:06
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 02/19 20:15
Insider Trends: Insider at Ligand Pharmaceuticals Makes Shares Sale for Tax Slowing 90-Day Buy Trend
MT Newswires · 02/18 18:37
Insider Trends: Ligand Pharmaceuticals Insider Sells Shares for Tax Slowing 90-Day Buy Trend
MT Newswires · 02/18 18:36
Insider Trends: Insider at Ligand Pharmaceuticals Makes Tax Sale Interrupting 90-Day Buy Trend
MT Newswires · 02/18 18:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LGND. Analyze the recent business situations of Ligand Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LGND stock price target is 224.67 with a high estimate of 310.00 and a low estimate of 198.00.
EPS
Institutional Holdings
Institutions: 468
Institutional Holdings: 26.54M
% Owned: 159.74%
Shares Outstanding: 16.61M
TypeInstitutionsShares
Increased
82
1.87M
New
66
-190.79K
Decreased
89
1.94M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
John Kozarich
President/Chief Operating Officer
Matthew Foehr
Chief Executive Officer/Director
John Higgins
Chief Financial Officer/Executive Vice President - Finance
Matthew Korenberg
Senior Vice President/General Counsel/Secretary
Charles Berkman
Independent Director
Jason Aryeh
Independent Director
Sarah Boyce
Independent Director
Todd Davis
Independent Director
Nancy Gray
Independent Director
John LaMattina
Independent Director
John Lamattina
Independent Director
Sunil Patel
Independent Director
Stephen Sabba
Declaration Date
Dividend Per Share
Ex-Div Date
03/20/2007
Dividend USD 2.5
04/03/2007
  • All
  • Financials
  • Insiders
More
About LGND
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Webull offers kinds of Ligand Pharmaceuticals Inc. stock information, including NASDAQ:LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.